News

ADRX-0405 is uniquely being tested during its 1a/b clinical trials. ADRX-0405 is labeled as a STEAP1 ADC (primarily ...
Life sciences marketing has long revolved around physicians. Traditionally seen as the gatekeepers of prescribing power, ...
Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...
Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...